Related Experiment Video

Updated: Jul 7, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

More nomograms or better evidence of efficacy: what do we need in urologic oncology?

James W F Catto

    European Urology
    |February 12, 2008
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    Related Experiment Videos

    Last Updated: Jul 7, 2026

    Establishing a Competing Risk Regression Nomogram Model for Survival Data
    04:57

    Establishing a Competing Risk Regression Nomogram Model for Survival Data

    Published on: October 23, 2020

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    Related Concept Videos

    Dosage Regimen Designs: Nomograms and Tabulations01:23

    Dosage Regimen Designs: Nomograms and Tabulations

    Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
    Cancer Survival Analysis01:21

    Cancer Survival Analysis

    Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

    Articles linked to this work by shared authors, journal, and citation graph.

    INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol.

    BJU international·2026

    State of the nation: Understanding the current NHS treatment pathway to identify opportunities to advance future care of patients with high-risk non-muscle invasive bladder cancer in the UK (SPAN-UK).

    BJUI compass·2026

    Comprehensive genome-wide association study into multiple recurrence and progression risk in non-muscle invasive bladder cancer.

    Cancer genetics·2026

    Update of the EORTC Health-related Quality of Life Modules for Bladder Cancer: Phase 1-2 of the Development Process.

    European urology oncology·2026

    Artificial Intelligence Remote Patient Monitoring for Predicting Overall Survival for Patients Undergoing Radical Cystectomy for Bladder Cancer: Exploratory Analysis of the Prospective Trial.

    JMIR AI·2026

    International Survey of Thromboprophylaxis Practices During Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.

    Clinical genitourinary cancer·2026

    Major Adverse Cardiovascular Events in Men with High-risk Localized or Metastatic Prostate Cancer Starting Long-term Hormone Therapy in the STAMPEDE Trial.

    European urology·2026

    Accumulating Evidence Supports NECTIN4 as a Predictive Biomarker for Enfortumab Vedotin: The Compartment Still Matters.

    European urology·2026

    PSMA-PET/CT-guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): 5-yr Analysis of a Phase 2 Randomized Controlled Trial.

    European urology·2026

    Guiding Risk Reduction for Breast Cancer-Relevant Chemicals (BC-Chems): Chemical Production Volumes, Sources, Intake Levels, Emissions, and Regulations.

    Environmental health perspectives·2026

    Integrated network toxicology and multi-omics profiling reveal cell cycle, DNA damage repair, and metabolic alterations in cyclophosphamide-induced premature ovarian insufficiency.

    Frontiers in pharmacology·2026

    Screening Bacteriuria Using the Sysmex UF-5000 during Intravesical Bacillus Calmette-Guérin Therapy for Bladder Cancer.

    Chonnam medical journal·2026

    Cannabis use and perceptions among rural and urban cancer patients and survivors from a Pennsylvania cancer center.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026

    BEHOLD-1 and -2: phase 1/2 randomized studies evaluating the B7 homolog 4 protein-targeted antibody-drug conjugate mocertatug rezetecan in patients with solid tumors, including endometrial and ovarian cancers.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026

    Selective cognitive changes in a multidrug mouse model of chemotherapy-induced adverse effects.

    Brain research·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us